[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
[e-drug] BMJ on HIV prevention
- From: firstname.lastname@example.org
- Date: Fri, 2 Dec 2005 08:23:47 +0000
E-DRUG: BMJ on HIV prevention
An editorial in today's BMJ (copied below) illustrates various actual or potential methods of prevention of HIV infection, namely reduction of high-risk (sexual) behaviour, vaccine, male circumcision, pre-exposure chemoprophylaxis, as well as judicious use of HAART in pregnant women, caesarian section, and infant chemoprophylaxis to reduce mother-to-child-transmission.
However, there is a deafening silence on reduction of non sexual high risk behaviour, ie that related to unhygienic health practices, in particular the excessive use of the parenteral route for the administration of drugs and the widespread re-use of needles. I don't think the controversy of how much of HIV infection is due to unsafe sex and how much is due to unsafe health practice is solved. However, before a whole continent (or two, or three) are condemned to the pursuit of chastity (unrealistic and unfair -whatever any religious or political organization may say) or to the practice of safe sex 100% of the time (also unrealistic), parallel ways of prevention of infection MUST be pursued.
My knowledge is insufficient to make such a comment in a scientific journal but if anyone has any figures on iatrogenic transmission of HIV infection or on the extent of unsafe health practice in the developing world, maybe they could.
Dr Valeria Frighi
Oxford Centre for Diabetes, Endocrinology and Metabolism
BMJ 2005;331:1285-1286 (3 December)
Preventing HIV infection
Needs urgent attention now that effective treatment is widely available
[Copied as fair use]
In 2002, the prevailing view was that preventive strategies, rather than the provision of highly active antiretroviral therapy (HAART), were the only feasible way to control the spread of HIV infection.1 Antiretroviral treatment is now cheaper, thanks to initiatives from the pharmaceutical industry and generic manufacture, and its wider availability encourages more people to seek HIV testing. In line with the "3 by 5"strategy, the World Health Organization aims to provide HAART for three million people by the end of 2005 while continuing to promote prevention. Provision of treatment may be hindered by availability or infrastructural capacity. To make a sustainable impact on the global epidemic of HIV infection, investment in prevention research, including biomedical prophylaxis, remains paramount. Various government campaigns aimed at increasing knowledge and modifying high risk behaviour have been temporally associated with reduced incidence and prevalence of HIV infection in a few countries, notably Thailand and Uganda.2 It remains unclear, however, whether these events are causally related. Phase III studies of potential vaccines against HIV have proved unsuccessful, but there is still hope for other preventive measures. For example, considerable research activity continues to investigate microbicides, with several compounds in development showing promise.3 The necessary phase III trials will not, however, yield results in the near future.
Male circumcision has also been studied widely as a possible preventive measure. Observational studies have suggested that circumcision reduces the risk of acquiring and transmitting HIV infection, although previous meta-analyses did not confirm this.4 A recent prospective randomised trial of early circumcision compared with delayed circumcision among more than 3000 uncircumcised young men was stopped prematurely because of the considerable benefit of early circumcision. Circumcision was offered to men in the intervention group immediately after randomisation and would be offered to those in the control group at the end of follow up. The trial was stopped at the interim analysis after a mean of 18.1 months. Twenty HIV infections occurred in the intervention group and 49 in the control group, corresponding to a rate ratio of 0.40 (95% confidence interval 0.24 to 0.68; P < 0.001). When controlling for behavioural factors, including sexual behaviour, condom use, and health seeking behaviour, this ratio corresponded to a protective effect of 61% (34% to 77%).5 These data are encouraging but should not elicit a false sense of security and neglect of further preventive measures.
Credit: RAJESH JANTILAC/AFP/GETTY IMAGES
The possibility of chemoprophylaxis before exposure to HIV has caused both interest and marked controversy. Research on monkeys has shown that the antiretroviral drug tenofovir, given up to 48 hours before and after intravenous exposure to HIV, prevents infection.6 More recent data show that oral tenofovir reduces, but does not obviate, the risk from subsequent mucosal exposure to the virus.7 Researchers gave tenofovir to 12 macaques daily, weekly, or not at all, followed by multiple rectal challenges with simian immunodeficiency virus (SIV). Although tenofovir seemed to protect the macaques initially, eventually all the animals became infected with repeated exposure to the virus.
Randomised controlled trials investigating the use of pre-exposure tenofovir in the prevention of HIV acquisition have recently begun in several countries in both less developed and resource rich settings. Many of these trials have proved extremely contentious,8 despite sponsorship or funding from the US National Institute of Allergy and Infectious Diseases, the University of New South Wales, the US Centers for Disease Control and Prevention, and the Bill and Melinda Gates Foundation, rather than the drug company that manufactures tenofovir.
In these ongoing double blinded trials, HIV negative participants were randomised to receive placebo or tenofovir. They were counselled about safer sex and methods of accessing care should they become infected with HIV. Activists have opposed the trials, citing inadequacies in the overall care of participants, the delivery of proved methods for HIV prevention, the provision of antiretroviral therapy to participants who became infected with HIV during the trial, and the mechanisms for community engagement. These difficulties have led to the closure of the pre-exposure studies in several countries.9
Preventing the transmission of HIV infection from mother to child remains a primary goal in the developing world, to emulate successes in Western countries where this risk is kept low through judicious use of HAART and caesarean section. Simply giving a single dose of the non-nucleoside reverse transcriptase inhibitor nevirapine has proved suboptimal in Africa, reducing sensitivity to the drug in a high proportion of mothers as well as offspring and compromising the future effectiveness of this treatment.10 However, short term combination therapy that includes nevirapine reduces the risk of such drug resistance.11 Given that HIV can be transmitted through breast feeding, strategies such as exclusive breast feeding, which is thought to reduce the risk of diarrhoea and infection in infants, treating mothers with HAART, or chemoprophylaxis for the baby may all reduce transmission rates.11-13
Rachael Jones, specialist registrar
Department of HIV and GU Medicine, Chelsea and Westminster Hospital, London SW10 9NH
Brian Gazzard, professor
Department of HIV and GU Medicine, Chelsea and Westminster Hospital, London SW10 9NH
Yasmin Halima, senior consultant
International AIDS Society (IAS), Ch. de l'Avanchet 33, CH-1216 Cointrin, Geneva, Switzerland
Competing interests: RJ has received an educational bursary from Gilead, manufacturer of tenofovir, in the last year. BG has received consultancy fees from Gilead in the past five years.
1. Creese A, Floyd K, Alban A, Guiness L. Cost effectiveness of HIV/AIDS interventions in Africa: a systematic review of the evidence. Lancet 2002;359: 1635-42.[CrossRef][ISI][Medline]
2. Kamali A, Quigley M, Nakiyingi J, Kinsman J, Kengeya-Kayondo J, Gopal R, et al. Syndromic management of sexually-transmitted infections and behaviour change interventions on transmission of HIV-1 in rural Uganda: a community randomised trial. Lancet 2003;361: 645-52..[CrossRef][ISI][Medline]
3. Jiang S, Liu S, Lu H, Neurath AR. Synergistic and complementary effects of the anti-HIV-1 microbicides CAP and UC781 in combination. IAS Conference on HIV Pathogenesis and treatment, Rio de Janeiro, 2005:abstract MoPp0103..
4. Halperin DT, Bailey RC. Male circumcision and HIV infection: 10 years and counting. Lancet 1999,354: 1813-5.[CrossRef][ISI][Medline]
5. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med 2005;2(11): e298.[CrossRef][Medline]
6. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270: 1197-9.[Abstract]
7. Subbarao S. Chemoprophylaxis with oral tenofovir dispropoxil fumarate delays but does not prevent infection in rhesus macaques given repeated rectal challenges of SHIV. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, 2005:abstract 136LB.
8. Cohen J. AIDS research. Cambodian leader throws novel prevention trial into limbo. Science 2004;305: 1092.
9. Ahmed K. Trial of antiretroviral for HIV prevention on hold. Lancet Infect Dis 2004;4: 597[Medline]
10. Jackson JB, Becker-Pergola G, Guay LA, Musoke P, Mracna M, Fowler MG, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000;14: 111-5.[CrossRef]
11. McIntyre JA, Martinson N, Gray GE, Hopley M, Kimira T, Robinson P, et al. Addition of short course Combivir to single dose Viramune for the prevention of mother to child transmission of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, 2005:abstract TuFoO2O4.
12. Iliff PJ, Piwoz EG, Tavengwa NV, Zunguza CD, Marinda ET, Nathoo KJ, et al. Early exclusive breastfeeding reduces the risk of postnatal HIV transmission and increases HIV-free survival. AIDS 2005;19: 699-708.[ISI][Medline]
13. European Collaborative Study. HIV-infected pregnant women and vertical transmission in Europe since 1986. AIDS 2001;15: 761-70.[CrossRef][ISI][Medline]